MADRIGAL PHARMACEUTICALS INCMDGL
ASignal's systematic analysis rates MDGL as Neutral.
Reflects the latest available analysis · analyzed Aug 28, 2026
The case on MDGL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (71.2% YoY)
- High gross margin (91.48%) indicating pricing power
- Positive MACD histogram expansion suggesting strengthening momentum
- Cash position exceeds total debt (current ratio 3.21x)
- Price above 20-day and 50-day moving averages
- Negative operating and net margins
- Negative return on equity (-53.31%) and return on assets (-17.84%)
- High forward P/E (56.49x) and elevated valuation metrics
- Negative free cash flow (-$80.47M)
- No Reddit sentiment data available
See the full verdict on MDGL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes MDGL
Most investors never get a second opinion, let alone several. ASignal runs MDGL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.